Markt für Tests auf erblichen Krebs in Nordamerika bis 2027 – regionale Analyse und Prognosen nach Diagnosetyp (Biopsie, Bildgebung); Technologie (Sequenzierung, PCR, Microarray); Endbenutzer (Krankenhaus, Kliniken, Diagnosezentren) und Land

Historic Data: 2016-2017   |   Base Year: 2018   |   Forecast Period: 2019-2027


No. of Pages: 132    |    Report Code: TIPRE00006806    |    Category: Life Sciences

North America Hereditary Cancer Testing Market

Der nordamerikanische Markt für Tests auf erblich bedingte Krebserkrankungen wird im Jahr 2027 voraussichtlich 3.247,37 Mio .

 

Das Wachstum des Marktes wird durch Faktoren wie das wachsende Bewusstsein für erblich bedingten Krebs und günstige Erstattungsszenarien vorangetrieben. Allerdings dürfte sich das Marktwachstum aufgrund der geschlechtsspezifischen Kluft bei Krebs-Gentests in der Region verlangsamen.

 

 

Personalisierte Medikamente sind dies eine vergleichsweise neue Idee, die es Ärzten ermöglicht, Medikamente basierend auf dem Erbprofil eines Patienten auszuwählen; Es handelt sich um einen sich entwickelnden Bereich im Gesundheitssektor. Die Methode reduziert nicht nur unerwünschte Nebenwirkungen, sondern erzielt auch in kurzer Zeit starke Ergebnisse. Beispielsweise führen Mutationen in BRCA1 und BRCA2 zu Brustkrebs. Allerdings liefert die Identifizierung der Art der Variation bei der Brustkrebspatientin wichtige Informationen für die Art der Behandlung. Daher ermöglichen personalisierte Medikamente die richtige Behandlung zur richtigen Zeit, was die Sterblichkeitsrate senkt. Aufgrund dieser Vorteile dürfte der Ansatz der personalisierten Medizin den Marktteilnehmern für Erbkrebstests viele Möglichkeiten eröffnen.

 

Es wird erwartet, dass die USA den Markt anführen in der Region Nordamerika auf die stark steigenden Forschungs- und Entwicklungsausgaben biopharmazeutischer Unternehmen zurückzuführen. Darüber hinaus konzentrieren sich verschiedene biopharmazeutische Unternehmen auf die Entwicklung neuer Krebspanels und direkt an Verbraucher gerichteter Tests. Unter Berücksichtigung der oben genannten Faktoren dürfte das Marktwachstum in den USA daher im Prognosezeitraum den größten Anteil in der Region Nordamerika ausmachen.

 

< strong>Ausstellung: Markteinnahmen und Prognosen für Tests auf erblich bedingte Krebserkrankungen in Mexiko bis 2027 (Mio. USD)

 

 

TESTS AUF ERBLICHEN KREBS IN NORDAMERIKA – MARKTSEGMENTIERUNG

 NACH DIAGNOSETYP

  • Biopsie
    • Blutprobe
    • Wangenabstrichprobe
  • Bildgebung

 

VON

TECHNOLOGIE

  • Sequenzierung
  • PCR
  • Microarray

 

NACH ENDBENUTZER

  • Diagnosezentren
  • Krankenhaus
  • Kliniken
< p> 

Unternehmensprofile

  • Biosero Inc.
  • Hologic Inc.
  • Koninklijke Philips NV
  • Quest Diagnostics Incorporated
  • Myriad Genetics, Inc.
  • Cancer Genetics Inc.
  • Invitae Corporation
  • < li>Myogenes
  • Strand Life Sciences Pvt. Ltd.
  • Pathway Genomics Corporation
  • CENTOGENE AG


North America Hereditary Cancer Testing Strategic Insights

Strategic insights for North America Hereditary Cancer Testing involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-hereditary-cancer-testing-market-strategic-framework.webp
Get more information on this report

North America Hereditary Cancer Testing Report Scope

Report Attribute Details
Market size in 2018 US$ 1,255.79 Million
Market Size by 2027 US$ 3,247.37 Million
Global CAGR (2019 - 2027) 11.6%
Historical Data 2016-2017
Forecast period 2019-2027
Segments Covered By Diagnosetyp
  • Biopsie
  • Bildgebung
By Technologie
  • Sequenzierung
  • PCR
  • Microarray
By Endbenutzer
  • Krankenhaus
  • Kliniken
  • Diagnosezentren
Regions and Countries Covered Nordamerika
  • USA
  • Kanada
  • Mexiko
Market leaders and key company profiles
  • Biosero Inc.
  • Hologic Inc.
  • Koninklijke Philips N.V.
  • Quest Diagnostics Incorporated
  • Myriad Genetics, Inc.
  • Cancer Genetics Inc.
  • Invitae Corporation
  • Myogenes
  • Strand Life Sciences Pvt. Ltd.
  • Pathway Genomics Corporation
  • Get more information on this report

    North America Hereditary Cancer Testing Regional Insights

    The regional scope of North America Hereditary Cancer Testing refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-hereditary-cancer-testing-market-geography.webp
    Get more information on this report

    The List of Companies - North America Hereditary Cancer Testing Market

    The List of Companies

    1. Biosero Inc.
    2. Hologic Inc.
    3. Koninklijke Philips N.V.
    4. Quest Diagnostics Incorporated
    5. Myriad Genetics, Inc.
    6. Cancer Genetics Inc.
    7. Invitae Corporation
    8. Myogenes
    9. Strand Life Sciences Pvt. Ltd.
    10. Pathway Genomics Corporation
    11. CENTOGENE AG

     

    Frequently Asked Questions
    How big is the North America Hereditary Cancer Testing Market?

    The North America Hereditary Cancer Testing Market is valued at US$ 1,255.79 Million in 2018, it is projected to reach US$ 3,247.37 Million by 2027.

    What is the CAGR for North America Hereditary Cancer Testing Market by (2019 - 2027)?

    As per our report North America Hereditary Cancer Testing Market, the market size is valued at US$ 1,255.79 Million in 2018, projecting it to reach US$ 3,247.37 Million by 2027. This translates to a CAGR of approximately 11.6% during the forecast period.

    What segments are covered in this report?

    The North America Hereditary Cancer Testing Market report typically cover these key segments-

  • Diagnosetyp (Biopsie, Bildgebung)
  • Technologie (Sequenzierung, PCR, Microarray)
  • Endbenutzer (Krankenhaus, Kliniken, Diagnosezentren)
  • What is the historic period, base year, and forecast period taken for North America Hereditary Cancer Testing Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Hereditary Cancer Testing Market report:

  • Historic Period : 2016-2017
  • Base Year : 2018
  • Forecast Period : 2019-2027
  • Who are the major players in North America Hereditary Cancer Testing Market?

    The North America Hereditary Cancer Testing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Biosero Inc.
  • Hologic Inc.
  • Koninklijke Philips N.V.
  • Quest Diagnostics Incorporated
  • Myriad Genetics, Inc.
  • Cancer Genetics Inc.
  • Invitae Corporation
  • Myogenes
  • Strand Life Sciences Pvt. Ltd.
  • Pathway Genomics Corporation
  • CENTOGENE AG
  • Who should buy this report?

    The North America Hereditary Cancer Testing Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Hereditary Cancer Testing Market value chain can benefit from the information contained in a comprehensive market report.